These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 2902722

  • 1. Linkage of HLA-DR beta specific restriction fragment length polymorphisms with Graves' disease.
    Boehm BO, Schifferdecker E, Kuehnl P, Schöffling K.
    Acta Endocrinol (Copenh); 1988 Oct; 119(2):251-6. PubMed ID: 2902722
    [Abstract] [Full Text] [Related]

  • 2. Studies of restriction fragment length polymorphism (RFLP) of DR and DQ genes in HLA-DR3 positive patients with Graves' disease or systemic lupus erythematosus.
    Garcia-Ameijeiras A, Gladman DD, Chan JY, Volpé R.
    Clin Invest Med; 1993 Oct; 16(5):326-32. PubMed ID: 7903231
    [Abstract] [Full Text] [Related]

  • 3. Genetic factors in autoimmune thyroid disease analyzed by restriction fragment length polymorphisms of candidate genes.
    Mangklabruks A, Cox N, DeGroot LJ.
    J Clin Endocrinol Metab; 1991 Aug; 73(2):236-44. PubMed ID: 1677360
    [Abstract] [Full Text] [Related]

  • 4. Immunogenetics of Graves' ophthalmopathy.
    Weetman AP, So AK, Warner CA, Foroni L, Fells P, Shine B.
    Clin Endocrinol (Oxf); 1988 Jun; 28(6):619-28. PubMed ID: 2908181
    [Abstract] [Full Text] [Related]

  • 5. HLA class II DNA genotypes in Graves' disease: clues to inheritance of the HLA-linked component of susceptibility.
    Fletcher J, Franklyn JA, McLachlan SM, Young E, Sheppard MC.
    Clin Endocrinol (Oxf); 1988 Nov; 29(5):539-47. PubMed ID: 2908104
    [Abstract] [Full Text] [Related]

  • 6. Implication of the HLA-DRB3 gene in Graves' disease: predominance of allele Dw24.
    Semana G, Allanic H, Quillivic F, Vallejo MT, Simon JP, Genetet B, Fauchet R.
    Hum Immunol; 1990 Oct; 29(2):143-9. PubMed ID: 1979072
    [Abstract] [Full Text] [Related]

  • 7. Tumor necrosis factor beta gene polymorphisms in Graves' disease.
    Badenhoop K, Schwarz G, Schleusener H, Weetman AP, Recks S, Peters H, Bottazzo GF, Usadel KH.
    J Clin Endocrinol Metab; 1992 Feb; 74(2):287-91. PubMed ID: 1346144
    [Abstract] [Full Text] [Related]

  • 8. Evidence against extended DR3-related haplotypes in Graves' disease.
    Weetman AP, McCorkle R.
    J Immunogenet; 1990 Dec; 17(6):403-7. PubMed ID: 1982883
    [Abstract] [Full Text] [Related]

  • 9. MHC-extended haplotypes in families of patients with Graves' disease.
    Ratanachaiyavong S, Lloyd L, Darke C, McGregor AM.
    Hum Immunol; 1993 Feb; 36(2):99-111. PubMed ID: 8096501
    [Abstract] [Full Text] [Related]

  • 10. C4A gene deletion: association with Graves' disease.
    Ratanachaiyavong S, Lloyd L, McGregor AM.
    J Mol Endocrinol; 1989 Sep; 3(2):145-53. PubMed ID: 2570594
    [Abstract] [Full Text] [Related]

  • 11. DX alpha gene polymorphism in Graves' disease.
    Weetman AP, Roe C, So A.
    Tissue Antigens; 1988 Jan; 31(1):1-4. PubMed ID: 2893470
    [Abstract] [Full Text] [Related]

  • 12. HLA-DR3 and variations of the T cell receptor beta gene in Graves' disease.
    Schifferdecker E, Manfras B, Kühnl P, Holzberger G, Boehm BO.
    Acta Endocrinol (Copenh); 1991 Jun; 124(6):658-60. PubMed ID: 1676865
    [Abstract] [Full Text] [Related]

  • 13. Class III alleles and high-risk MHC haplotypes in type I diabetes mellitus, Graves' disease and Hashimoto's thyroiditis.
    Skanes VM, Barnard J, Farid N, Marshall WH, Murphy L, Rideout D, Taylor R, Xidos G, Larsen B.
    Mol Biol Med; 1986 Apr; 3(2):143-57. PubMed ID: 3461234
    [Abstract] [Full Text] [Related]

  • 14. Association of HLA antigen and restriction fragment length polymorphism of T cell receptor beta-chain gene with Graves' disease and Hashimoto's thyroiditis.
    Ito M, Tanimoto M, Kamura H, Yoneda M, Morishima Y, Yamauchi K, Itatsu T, Takatsuki K, Saito H.
    J Clin Endocrinol Metab; 1989 Jul; 69(1):100-4. PubMed ID: 2567295
    [Abstract] [Full Text] [Related]

  • 15. T cell receptor beta chain gene polymorphisms in Graves' disease.
    Pickerill AP, Watson PF, Tandon N, Weetman AP.
    Acta Endocrinol (Copenh); 1993 Jun; 128(6):499-502. PubMed ID: 8101679
    [Abstract] [Full Text] [Related]

  • 16. Molecular analysis distinguishes two HLA-DR3-bearing major histocompatibility complex extended haplotypes.
    Wescott MZ, Awdeh ZL, Yunis EJ, Alper CA.
    Immunogenetics; 1987 Jun; 26(6):370-4. PubMed ID: 2889669
    [Abstract] [Full Text] [Related]

  • 17. The role of HLA antigens in the manifestation and course of Graves' disease.
    Stenszky V, Kozma L, Balazś C, Bear JC, Farid NR.
    Mol Biol Med; 1986 Feb; 3(1):53-62. PubMed ID: 3485758
    [Abstract] [Full Text] [Related]

  • 18. DQA2 U allele: a genetic marker for relapse of Graves' disease.
    Ratanachaiyavong S, Gunn CA, Bidwell EA, Darke C, Hall R, McGregor AM.
    Clin Endocrinol (Oxf); 1990 Feb; 32(2):241-51. PubMed ID: 1971775
    [Abstract] [Full Text] [Related]

  • 19. HLA-DPB1 polymorphisms on the MHC-extended haplotypes of families of patients with Graves' disease: two distinct HLA-DR17 haplotypes.
    Ratanachaiyavong S, McGregor AM.
    Eur J Clin Invest; 1994 May; 24(5):309-15. PubMed ID: 8088306
    [Abstract] [Full Text] [Related]

  • 20. Multivariate analysis of HLA loci in conjunction with a thyrotropin receptor codon 52 polymorphism in conferring risk of Graves' disease.
    Cuddihy RM, Schaid DS, Bahn RS.
    Thyroid; 1996 Aug; 6(4):261-5. PubMed ID: 8875744
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.